Signadori Bio

Paris, France

Signadori Bio is the next-generation cellular immunotherapy for cancer cure.

$13.0M raised

May 2026

Seed

Manufacturing Oncology Pharmaceutical Therapeutics

Top Investors

Taiho Ventures Sofinnova Partners Invivo Capital Partners

Founder Contacts

30,000+ verified contacts

Get Instant Access

Emails, phones & LinkedIn profiles

Frequently Asked Questions about Signadori Bio

How much funding has Signadori Bio raised?

Signadori Bio has raised $13.0M in total funding. The most recent round was Seed. The last funding was announced in May 2026.

Who are Signadori Bio's investors?

Signadori Bio's investors include Taiho Ventures, Sofinnova Partners, Invivo Capital Partners.

Where is Signadori Bio headquartered?

Signadori Bio is headquartered in Paris, France.

What does Signadori Bio do?

Signadori Bio is the next-generation cellular immunotherapy for cancer cure.

What stage is Signadori Bio at?

Signadori Bio is at the Seed stage.

Cite this page

Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated May 6, 2026.

MLA

"Signadori Bio — Funding & Investors." VCBacked, May 6, 2026, https://www.vcbacked.co/company/signadori-bio. Accessed July 3, 2026.

APA

VCBacked. (2026). Signadori Bio — Funding & Investors. Retrieved July 3, 2026, from https://www.vcbacked.co/company/signadori-bio

Wikipedia (cite web)

{{cite web |title=Signadori Bio — Funding & Investors |url=https://www.vcbacked.co/company/signadori-bio |website=VCBacked |access-date=July 3, 2026}}

Profile data sourced and verified per the VCBacked methodology. Last funding round dated May 6, 2026.

Similar Companies in Manufacturing